Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This research is being done to test the safety of the combination of the study drugs
fostamatinib and paclitaxel. This study tests different doses of the drugs to see which doses
are safest in people with ovaria cancer when given together.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) Rigel Pharmaceuticals